Masakazu Sugi

Functional recovery of swallowing, speech, and taste in an oral cancer patient with subtotal glossectomy

5. Dinsworth AR, Byrd DL, Allen JW: Zygomatic complex 7. Laskin D: Oral and Maxillofacial Surgery, vol 2. St Louis. fracture with an avulsed tooth causing malocclusion: reCV Mosby, 1985, pp 79-80 port of case. J Oral Surg 32: 131, 1974 8. Winkler T. von Wowern N. Bittmann S: Retrieval of an 6. Kruger GO: Textbook of Oral and Maxillofacial Surgery, 6th upper third molar from the infratemporal space. J Oral ed. St Louis, CV Mosby, 1985, p 101 Surg 30:730-733. 1970: 35:130. 1977

Establishment of three bleomycin-resistant human carcinoma cell lines and their cross-resistance to other antitumor agents

Three bleomycin‐resistant (BLMr) human carcinoma cell lines (HeLa‐BLMr, KB‐BLMr, and Hepd‐uvBLMr) were established in culture by progressively increasing the concentration of bleomycin (BLM). HeLa‐BLMr and KB‐BLMr were obtained after 5 and 2 months of incubation with BLM, whereas the establishment of Hepd‐uvBLMr required 3 months of incubation with BLM after ultraviolet treatment. These cells have been successfully subcultured for more than 150 passages during more than 2 years in the presence of 1 μg/ml of BLM. The degrees of BLM resistance were 20‐fold, 11.6‐fold, and 186‐fold for HeLa‐BLMr, KB‐BLMr, and Hepd‐uvBLMr, respectively, and the resistant phenotype of both HeLa‐BLMr and Hepd‐uvBLMr was stable when they were cultured for 30 passages in BLM‐free medium, but unstable in KB‐BLMr. Although each cell line exhibited cross‐resistance to 3 to 5 other antitumor agents including peplomycin, combined use of BLM with a polyene antibiotic, a calcium channel blocker, or a poly(ADP‐ribose) polymerase inhibitor overcame the BLM resistance in vitro to various degrees.

Further Characterization of Bleomycin-resistant HeLa Cells and Analysis of Resistance Mechanism

Bleomycin (BLM)‐resistant HeLa cells (HeLa‐BLMr), which have been subcultured for more than 150 passages during over 2 years in the presence of 1 μg/ml of BLM and stably possess a 20‐fold‐increased BLM‐resistance in vitro, were further characterized. The nude mouse tumors produced by HeLa‐BLMr were significantly less sensitive (P < 0.005–0.01) to BLM administration than those produced by HeLa cells, and the cells primarily cultured from nude mouse tumors of HeLa‐BLMr and transplanted serially 5 times in the absence of BLM also exhibited a similar degree of BLM resistance to that of HeLa‐BLMr cultured in BLM‐containing medium. The BLM‐resistance mechanism of HeLa‐BLMr was partially analyzed. The cells showed about 40% decreased accumulation and 2–3 times reduced retention of [3H]peplomycin, a novel BLM analog, as compared to HeLa cells, but the BLM‐hydrolase activity was at almost the same level as that of HeLa cells when determined by HPLC. Furthermore, alkaline sucrose gradient analysis of cellular DNA after BLM treatment revealed that the damaged DNA was more efficiently repaired in HeLa‐BLMr than in HeLa cells. These results suggest that decreased drug accumulation and retention, and elevated DNA repair activity are the main mechanisms of BLM resistance in HeLa‐BLMr.

Ig A · K type myeloma with severe postextraction bleeding

A case of multiple myeloma detected by the first symptom of severe postextraction bleeding was presented. Although laboratory data showed severe anemia, rouleaux formation of erythrocytes, abnormal hemostatic parameters, elevated erythrocyte sedimentation rate and hyperglobulinemia, no involvement of bones such as the jaws, skull, ribs or sternum was demonstrated roentgenologically. Final diagnosis obtained by immunoelectrophoresis was Ig A . K type myeloma. During a therapeutic period with melphalan and predonine, bleeding from the extracted wound was repeated. 2 months after the onset of the first symptoms, the patient died of systemic bleeding. Autopsy findings revealed many hemorrhagic sites in the lungs, stomach, kidney and bladder and the existence of plasma cell-like tumor cells in the bone marrow of lumber vertebra and sternum.

Effect of a bleomycin derivative on oral carcinoma: A clinical and immunologic study of five cases

A new bleomycin derivative NK631 was administered in five cases of advanced recurrent oral carcinoma. The visible improvement of the tumor was noted in three cases, and in the cases of lower lip carcinoma the tumor completely disappeared, however, there was no effective change in cases of cervical metastases of the floor of the mouth and tongue carcinoma. The peripheral lymphocyte counts and serum proteins disclosed a characteristic decrease, serum proteins decreased in the albumin fraction and slightly increased in alpha 2-globlin fraction. Main side effects of NK 631 were skin exanthema, alopecia, anorexia, pyrexia, fatigue and bleeding from the tumor lesion. Regarding the lung function, the vital capacity did not change, but PaO and PaCO in blood gas analysis were together observed to slightly decrease, and it may be supposed that the influence of NK631 on the lung function cannot be neglected. T-cell ratio, lymphocyte blastoformation following PHA stimulation, PPD and DNCB skin tests, and phagocytosis test of peripheral leucocytes were studied. The immuno-suppressive effect of KK631 was the same or weak as bleomycin.